PF-Atlas › Clinical Trials › NCT00879229
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
Ambrisentan · Phase 3
Registry ID
NCT00879229
Phase
Phase 3
Status
Terminated
Drug / intervention
Ambrisentan
Sponsor
Gilead Sciences
Start
2009-07
About this trial
Ambrisentan is evaluated in NCT00879229, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Gilead Sciences. Current status: Terminated.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00879229 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.